Circio converts bonds, increasing share capital

Circio Holding ASA has confirmed the conversion of convertible bonds with a nominal value of NOK 2,500,000, previously issued to Atlas Special Opportunities, LLC. This conversion will result in the issuance of 4,146,166 new shares in Circio at a conversion price of NOK 0.60297 per share.

Upon registration, the company's share capital will increase by NOK 2,487,699.60. Following this conversion, Circio's total share capital will be NOK 67,792,746.00, divided into 112,987,910 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA is a biotechnology company focused on developing circular RNA vector expression technology for next-generation nucleic acid medicine through its proprietary circVec platform, and continues to advance its legacy immuno-oncology program, TG01, for RAS-mutated cancers.